Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. [artículo]
Por: Gómez Martín, Carlos [Oncología Médica]
.
Colaborador(es): Servicio de Oncología Médica.
Editor: Clinical & translational oncology, 2012Descripción: 14(9):689-97.Recursos en línea: Solicitar documento
En: Resumen: Hand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC4436 (Navegar estantería) | Disponible |
Formato Vancouver:
Gómez-Martin C, Sánchez A, Irigoyen A, Llorente B, Pérez B, Serrano R, et al. Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. Clin Transl Oncol. 2012 Sep;14(9):689-97.
PMID: 22855151
Contiene 27 referencias
Hand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy.
No hay comentarios para este ejemplar.